InflaRx (IFRX) to Release Earnings on Thursday

InflaRx (NASDAQ:IFRX) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $0.0260 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 19, 2026 at 9:30 AM ET.

InflaRx Stock Up 0.4%

Shares of NASDAQ IFRX opened at $0.91 on Wednesday. InflaRx has a twelve month low of $0.71 and a twelve month high of $1.94. The firm has a market cap of $61.31 million, a PE ratio of -1.34 and a beta of 1.48. The business has a fifty day simple moving average of $0.94 and a two-hundred day simple moving average of $1.16.

Institutional Investors Weigh In On InflaRx

Institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd acquired a new position in InflaRx during the 4th quarter worth about $135,000. Suvretta Capital Management LLC grew its position in InflaRx by 22.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after acquiring an additional 1,450,000 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in InflaRx during the fourth quarter worth about $104,000. Squarepoint Ops LLC increased its stake in InflaRx by 72.0% during the fourth quarter. Squarepoint Ops LLC now owns 324,349 shares of the company’s stock worth $328,000 after purchasing an additional 135,826 shares during the period. Finally, HRT Financial LP acquired a new stake in shares of InflaRx during the fourth quarter worth about $47,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

Wall Street Analyst Weigh In

IFRX has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of InflaRx in a report on Tuesday, December 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research report on Monday, December 29th. Raymond James Financial restated an “outperform” rating on shares of InflaRx in a report on Wednesday, December 31st. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price target (down from $5.00) on shares of InflaRx in a research report on Wednesday, December 3rd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.